or “SORKON” and its subsidiaries (“the company”) would like to clarify the operating results for Quarter 2/2020 as follows: Revenue and Net Sales The Company recorded its total revenue of Baht 699.9

compared to total revenue from medical treatment in the 1st quarter of Year 2020 equaled to 79.0%, and in the 1st quarter of Year 2019 equaled to 80.2%. A decrease of nearly 1.2% in the cost of medical

maintain its strong economic fundamentals, with a current account surplus of USD 37.3 billion, approximately 6.8 percent of GDP, and international reserves standing at 1.3 times its total foreign-currency

to receive one-third of the capacity of PTA and PET produced at the Corpus Christi Project upon completion. The value of the above transaction for IVL, calculated in accordance with the regulations of

. Sutasanee Karnasuta Objectives of bor rowing To enhance the company’s liquidity Borrowing amount Total amount 20,000,000 Baht which are: 1. 12,000,000 Baht by K Alliance Company Limited 2. 8,000,00 Baht by

104.6 105.6 109.8 109.8 Total loan loss reserve/ Total mandatory reserve 187.8 187.8 188.1 185.1 185.4 188.6 188.6 3 Operating Performance for the year 2017 Profit and Loss Transaction For the year ended

shares of Co-Mass Company Limited (“COMASS”) with total investment of THB 160mn, thereby increasing MACO’s stake in COMASS to 100.0%. As a result, MACO fully controls COMASS, allowing us to utilise

Transaction in accordance with the Securities and Exchange Commission and Stock Exchange of Thailand Notifications, total 8.96 million Baht, which is calculated to be 0.08% of the Company’s Net Tangible Assets

over CAZ. The transaction is considered the disposition of assets in accordance with the Notification of the Capital Market Supervisory Board No. Tor Chor 20/2551 re: Rules on Entering into Materials

and its subsidiaries’ operating results for the quarter ended March 31st 2018 Unit: THB Million Q1/2017 Q4/2017 Q1/2018 YoY QoQ Total Revenue 43,995 46,306 44,226 1% -4% Accounting EBITDA 4,075 3,494